Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 18/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177067 | 1.00 | CTSA (0.45) | CTSAPKMSLC7A5 | |
| SCHEMBL6179589 | 1.00 | CTSA (0.45) | CTSAPKMSLC7A5 | |
| SCHEMBL27535196 | 0.84 | ESR1 (0.41) | CTSAPKM | |
| SCHEMBL27535188 | 0.82 | PKM (0.42) | CTSAPKM | |
| SCHEMBL3519472 | 0.78 | CTSA (0.61) | CTSA | |
| SCHEMBL2039261 | 0.76 | CTSA (0.48) | CTSA | |
| SCHEMBL6493992 | 0.76 | CTSA (0.46) | CTSAPKM | |
| SCHEMBL6176693 | 0.76 | PKM (0.44) | PKMSLC7A5 | |
| SCHEMBL7825710 | 0.75 | CTSA (0.47) | CTSA | |
| SCHEMBL6177437 | 0.74 | MIF (0.42) | PKMSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | CTSA 1169/4885PKM 4524/4885SLC7A5 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.